I didn't see a specific thread for beta blockers so I am creating this one.
I found this study while researching any linkage between beta blockers and Parkinson's disease.
Maybe someone with knowledge of the statistics used in these studies can tell me what the bolded part in the results below means in real life and common language.
pubmed.ncbi.nlm.nih.gov
Which has the results and conclusion:
Results: Overall, 145,098 patients received β-blockers, and 1,187,151 patients did not. The adjusted hazard ratio for Parkinson's disease among β-blocker users was 1.51 (95% confidence interval 1.28-1.77; p < 0.0001).
Conclusions: Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson's disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.
I found this study while researching any linkage between beta blockers and Parkinson's disease.
Maybe someone with knowledge of the statistics used in these studies can tell me what the bolded part in the results below means in real life and common language.
Chronic Use of β-Blockers and the Risk of Parkinson's Disease
![pubmed.ncbi.nlm.nih.gov](/forum/proxy.php?image=https%3A%2F%2Fcdn.ncbi.nlm.nih.gov%2Fpubmed%2Fpersistent%2Fpubmed-meta-image-v2.jpg&hash=9b8e02b45800bb46454d77e028532ca2&return_error=1)
Chronic Use of β-Blockers and the Risk of Parkinson's Disease - PubMed
Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson's disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.
![pubmed.ncbi.nlm.nih.gov](/forum/proxy.php?image=https%3A%2F%2Fcdn.ncbi.nlm.nih.gov%2Fcoreutils%2Fnwds%2Fimg%2Ffavicons%2Ffavicon.png&hash=5c808a419f0b4431032615073781b161&return_error=1)
Which has the results and conclusion:
Results: Overall, 145,098 patients received β-blockers, and 1,187,151 patients did not. The adjusted hazard ratio for Parkinson's disease among β-blocker users was 1.51 (95% confidence interval 1.28-1.77; p < 0.0001).
Conclusions: Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson's disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.